Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 PK Food Effect and Bedtime Dosing Study
NCT02222168Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of osoresnontrine in Alzheimer's disease (AD) and schizophrenia (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Measured Concentration at 24 hours and Area Under the Concentration-time Curve from Time 0 to Last Quantifiable Data Point at 24 hours. Started Sep 2014; status: completed.
02
Drugs
osoresnontrine
03
Conditions
Alzheimer's disease (AD)schizophrenia
Beyond the preview
Go deeper on NCT02222168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02222168.